Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

BiTE

- PMLiVE

AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn

SIM0500 is in phase 1 development for patients with relapsed or refractory cases of the blood cancer

- PMLiVE

Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma

Approximately 32,000 people are diagnosed with the haematological malignancy in the US every year

- PMLiVE

Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

There is currently no national screening programme for prostate cancer in the UK

- PMLiVE

Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults

SCLC accounts for approximately 15% of all lung cancer diagnoses and progresses rapidly

- PMLiVE

Amgen’s Blincyto granted MHRA approval for new acute lymphoblastic leukaemia indication

Approximately 300 new adult cases of the blood cancer are diagnosed in the UK every year

- PMLiVE

J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma

The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

- PMLiVE

Amgen announces $1bn investment to establish new US drug manufacturing facility

The expansion in North Carolina builds on the company’s previous $550m commitment in the area

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

Amgen’s investigational weight-loss drug MariTide shows promise in mid-stage study

The company has announced a phase 3 programme across obesity and related conditions

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

J&J submits EU and US applications for subcutaneous Darzalex in smouldering multiple myeloma

The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

- PMLiVE

AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial

The severe asthma drug met both of the late-stage study’s co-primary endpoints

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links